Duncan Mckechnie Sells 1,541 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Duncan Mckechnie sold 1,541 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at $5,709,519. This represents a 12.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Stock Down 1.4%

Shares of VRTX stock traded down $7.34 on Tuesday, reaching $522.25. The company had a trading volume of 2,292,336 shares, compared to its average volume of 1,470,929. The business’s 50-day moving average is $449.37 and its 200 day moving average is $456.46. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $533.67. The stock has a market capitalization of $132.55 billion, a PE ratio of 30.98, a price-to-earnings-growth ratio of 2.26 and a beta of 0.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. During the same period in the previous year, the business earned $4.06 EPS. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of VRTX. Brighton Jones LLC boosted its stake in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. Gamco Investors INC. ET AL bought a new position in shares of Vertex Pharmaceuticals during the second quarter valued at $228,000. NewEdge Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 9.0% during the second quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company’s stock valued at $5,311,000 after buying an additional 986 shares during the last quarter. ICW Investment Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 5.0% during the second quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock valued at $269,000 after buying an additional 29 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its holdings in Vertex Pharmaceuticals by 26.3% in the 2nd quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company’s stock worth $3,246,000 after buying an additional 1,518 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex’s acquisition of Crinetics gives it access to an approved rare-disease therapy and additional late-stage pipeline assets, strengthening its growth outlook and potentially expanding annual revenue over time. Vertex to Acquire Crinetics Pharmaceuticals
• Positive Sentiment: Broader sentiment around biotech has improved, with Jim Cramer calling the sector “the hottest group in the market” and suggesting merger activity could accelerate, which may support investor enthusiasm for Vertex’s deal-making strategy. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Neutral Sentiment: Analysts and market commentary are also focusing on how the acquisition may reshape Vertex’s pipeline and valuation, with some investors weighing the strategic benefits against the size of the cash outlay. Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
• Neutral Sentiment: A separate law-firm investigation into Crinetics’ board could add some legal noise around the transaction, but it is aimed at CRNX rather than Vertex and appears secondary to the acquisition itself. Shareholder Notice: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
• Negative Sentiment: Some traders may view the deal size as a near-term drag on Vertex shares, since large acquisitions can pressure margins, increase integration risk, and require investors to wait for synergies to show up in results. Vertex to buy Crinetics in $10 billion deal

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VRTX. Weiss Ratings downgraded shares of Vertex Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Citigroup boosted their target price on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Barclays increased their price target on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Oppenheimer lifted their price target on Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. Finally, Morgan Stanley upped their price objective on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research note on Tuesday, May 5th. Twenty-one analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $557.09.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.